Actively Recruiting
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Led by Mazandaran University of Medical Sciences · Updated on 2025-04-27
100
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
CONDITIONS
Official Title
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Recent ischemic stroke within 24 hours diagnosed by brain CT or MRI
- Mild stroke with NIH Stroke Scale score of 8 or less and no large infarct on brain imaging
- High risk transient ischemic attack with ABCD score greater than 4
- No cardioembolic sources such as low ejection fraction, mitral stenosis, or atrial fibrillation
- No specific causes such as dissection or vasculitis
- No carotid artery narrowing greater than 50% on the affected side
You will not qualify if you...
- History of allergic reaction to the study drugs
- Any reason to require anticoagulant therapy
- Received intravenous thrombolysis or thrombectomy in the acute phase
- Any contraindication to the study drugs
- History of brain bleeding
- History of gastrointestinal bleeding in the past 6 months
- Candidate for carotid endarterectomy
- History of blood clotting disorders
- Active bleeding tendency at the time of randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mazandaran province, Sari,Iran
Sari, Mazandaran, Iran, 4817844718
Actively Recruiting
Research Team
A
Athena Sharifi Razavi, MD
CONTACT
N
Nasim Tabrizi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here